您好，欢迎光临世界标品！ 登录 注册（订药物标准品请用邮件联系我们）

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索（中英文）：
世界各国官方药品目录搜索（英文）：
世界标品医药知识搜索（中英文）：

美国药房|加拿大药房|英国药房|瑞士药房|澳大利亚药房|新西兰药房|香港药房|印度药房|新加坡药房|俄罗斯药房|法律的依据
日本药房|德国药房|孟加拉药房|巴西药房|欧洲共同体药房|土耳其药房|以色列药房|法国药房|罗马尼亚药房|墨西哥药房|爱尔兰药房
荷兰药房|意大利药房|保加利亚药房|南非药房|芬兰药房|挪威药房
联系方式
国内客服电话：
国际免费电话：

咨询邮箱：
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 神经系统药物->解热镇痛药物
处方药:处方药
包装规格: 250毫升/瓶
计价单位:
   
生产厂家英文名:
 EAGLE PHARMS
该药品相关信息网址1:
 http://www.ryanodex.com/
该药品相关信息网址2:
 http://www.rxlist.com/ryanodex-drug.htm
 原产地英文商品名:
 Ryanodex 250mg vial
原产地英文药品名:
 DANTROLENE SODIUM
中文参考商品译名:
 Ryanodex 250毫升/瓶
中文参考药品译名:
 丹曲林钠静脉注射悬液
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
 malignant hyperthermia
 临床试验期:
 完成
中文适应病症参考翻译1:
 恶性高热
药品信息:
英文药名: Ryanodex（dantrolene sodium injectable suspension） 中文药名: 丹曲林钠静脉注射悬液 生产厂家: Eagle Pharmaceuticals Inc 药品说明 FDA批准纳米丹曲林钠注射用混悬液治疗恶性高热 Eagle制药公司于 7月23日宣布，美国FDA批准Ryanodex®（dantrolene sodium injectable suspension，纳米丹曲林钠注射用混悬液）伴以相应的支持措施治疗恶性高热（malignant hyperthermia，MH）。MH是一种遗传性和可能致命的疾病由某些麻醉剂在基因易感个体身上触发。Ryanodex在2013年8月被FDA认定为罕用药。在未来4至6周内，FDA将通知Eagle公司是否获得7年市场独占权。 Ryanodex是30多年以来首个获准的改善MH治疗的药物。它可能成为MH治疗的新标准，因为它为麻醉医师提供一种比现有的静脉注射剂（Dantrium IV）更为便利的制剂，可由保健医师独自在1分钟内完成注射，从而能挽救生命和减少MH相关疾病发生率和死亡率。 采用创新的纳米混悬剂技术，Ryanodex以单次治疗剂量（250毫克丹曲林钠/5毫升灭菌水安瓶提供。Dantrium IV则需要将多个20毫克丹曲林钠安瓶以大量灭菌水配制，这个过程可能需要15至20分钟。 美国MH协会主席Henry Rosenberg指出：“当患者在手术过程中遇到MH时，需要立即以包括丹曲林钠等紧急处置。Ryanodex提供了MH危象迅速控制和严重并发症预防的有效手段。” 包装规格：250mg/瓶 RYANODEX®注射用混悬液 RYANODEX®makes dantrolene sodium administration faster and easier than other alternatives. RYANODEX®(dantrolene sodium) for injectable suspension is indicated for the1: •Treatment of malignant hyperthermia in conjunction with appropriate supportive measures •Prevention of malignant hyperthermia in patients at high risk •Less than 1 minute for reconstitution and administration of a loading dose (2.5 mg/kg) in an MH crisis2,3 ◦Fewer vials required to treat MH (1 vial contains 250 mg of dantrolene sodium)1,9,10 ◦1 vial of RYANODEX® contains the same amount of dantrolene sodium as 12.5 vials of other approved dantrolene sodium formulations1,9,10 •Over 99% less sterile water for injection than other dantrolene sodium IV treatments1,9,10 •1 vial provides a loading dose (2.5 mg/kg) for patients up to 100 kg.1,3 ◦Can be reconstituted and administered by 1 healthcare professional (eg, an anesthesia provider) RYANODEX® is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia (MH), including: •Discontinuing triggering anesthetic agents •Increasing oxygen •Managing the metabolic acidosis •Instituting cooling when necessary •Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX® is insufficient to maintain diuresis) The RYANODEX® MH protocol simplifies and expedites the treatment of MH, and may help reduce overall risk for a facility. See how these changes affect you. Anesthesia Providers •Reduce the time to administer a therapeutic dose of dantrolene sodium •Simplify treatment process for the entire team Pharmacy Directors •Reduce the number of vials to be stored in each facility •Eliminate the requirement to store large volumes of sterile water on an MH cart •Make the reconstitution and administration of dantrolene sodium faster and more convenient Risk Managers •Reduce the probability of MH-treatment–related complications by shortening the time of administration for dantrolene sodium and reducing fluid volume administered in an MH crisis Important Safety Information Fatalities have been reported in patients who, despite initial satisfactory response, could not be weaned from dantrolene sodium after initial treatment. The administration of dantrolene sodium is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following dantrolene sodium administration. Tissue necrosis secondary to extravasation has also been reported, in addition to injection site reactions (pain, erythema, swelling), which are commonly due to extravasation. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.
更新日期: 2014-08-24
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间：太平洋时间18:00-24:00
国内客服电话：     国际免费电话：
友情提示：以上电话为免费电话，无需您承担任何费用，世界标品提供中文客服，请您放心拨打！
电子邮箱：sciteck.hongkong@gmail.com, 15901965168@163.com